We now have about seventy patients enrolled, but we hope to be able to include about 600! We are waiting for your cooperation. Our objective is to have an epidemiological, clinical and outcome profile of patients with resistant prolactinomas (using high dose cabergoline – > 3 mg/week).
Please contact Dr Krystallenia Alexandraki, ([email protected])
https://www.synergy2go.com/index.php
You must be logged in to post a comment.